Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO5429083 + cytarabine
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
RO5429083 + cytarabine is an investigational combination therapy for hematologic malignancies, notably acute myeloid leukemia. RO5429083 (also known as RG7356) is a humanized IgG1 monoclonal antibody targeting CD44, a cell surface glycoprotein implicated in tumor growth, metastasis, and resistance pathways. Cytarabine is a well-established nucleoside metabolic inhibitor (antimetabolite) that inhibits DNA synthesis, primarily used in acute myeloid leukemia. This combination has been evaluated in phase 1 clinical trials, with preclinical data supporting a synergistic anti-leukemic effect through targeting of both proliferative and survival pathways in leukemia cells.
- Other names
- RG7356 + cytarabine
02
Targets
CD44 (CD44 antigen)DNA polymerase family
Beyond the preview
Go deeper on RO5429083 + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO5429083 + cytarabine.